Live News EQUITY FLASH L impact Oct 27, 2026, 12:12 PM UTC OPKO Biologics Doses First Participant in Phase 1/2a Acromegaly Study OPKO Biologics dosed the first participant in a Phase 1/2a study for acromegaly. OPK SquawkNews Desk